Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12
Benchmark Initiates Coverage On Intensity Therapeutics With Speculative Buy Rating, Announces Price Target of $12
Benchmark以投機性買入評級啓動對Intensity Therapeutics的報道,宣佈目標股價爲12美元
Benchmark analyst Robert Wasserman initiates coverage on Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy rating and announces Price Target of $12.
基準分析師羅伯特·瓦瑟曼開始對Intensity Therapeutics(納斯達克股票代碼:INTS)進行投機性買入評級,並宣佈目標股價爲12美元。